Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 1 of 57 PageID #: 26333
`Case 1:18—cv-00924-CFC Document 344-2 Filed 08/27/19 Page 1 of 57 PageID #: 26333
`
`
`
`
`
`
`
`
`
`
`
`
`
`EXHIBIT B
`
`EXHIBIT B
`
`
`
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 2 of 57 PageID #: 26334
`
`IN THE UNITED STATES DISTRICT COURT
`FOR THE DISTRICT OF DELAWARE
`
`GENENTECH, INC. and CITY OF HOPE,,
`
`PlaintiffsPlaintiff,
`
`C.A. No. 18-924-CFC
`
`v.
`
`AMGEN INC.,
`
`Defendant.
`
`CONFIDENTIAL - FILED UNDER SEAL
`
`JURY TRIAL DEMANDED
`
`SECONDTHIRD AMENDED COMPLAINT
`
`PlaintiffsPlaintiff Genentech, Inc. (“Genentech”) and City of Hope (collectively,
`
`“Plaintiffs”) bring this Secondbrings this Third Amended Complaint for declaratory and injunctive
`
`relief against Defendant Amgen Inc. (“Amgen”) to address Amgen’s infringement of patents
`
`relating to Genentech’s groundbreaking breast cancer drug Herceptin®.
`
`NATURE OF THE CASE
`
`1.
`
`Breast cancer is a serious disease affecting over 2.8 million women in the United
`
`States. Approximately 20-25% of those women suffer from “HER2-positive” breast cancer. This
`
`is a particularly aggressive form of the disease characterized by overexpression of human
`
`epidermal growth factor receptor 2 (i.e., “HER2”) proteins due to excessive HER2 gene
`
`amplification.
`
`2.
`
`In the early 1990s, a diagnosis of HER2-positive breast cancer was effectively a
`
`death sentence: patients had an average life expectancy of only 18 months. The quality of life for
`
`those patients was markedly poor—the disease rapidly metastasized (i.e., spread to other parts of
`
`the body). The only available treatments were invasive and disfiguring surgery and
`
`ME1 29001636v.1
`
` 1 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 3 of 57 PageID #: 26335
`
`chemotherapeutic drugs with harsh side effects, and those treatments added little to the patient’s
`
`life span.
`
`3.
`
`The treatment of HER2-positive breast cancer, and the lives of millions of women
`
`suffering from the disease, changed dramatically with Genentech’s development of Herceptin®.
`
`Herceptin® was the first drug of its kind—an antibody called trastuzumab that specifically targeted
`
`the biological mechanism that makes HER2-positive breast cancer such an aggressive form of the
`
`disease.
`
`4.
`
`Although the scientific community was initially skeptical that such an antibody-
`
`based therapy could work, Genentech’s specific methods of using Herceptin® proved remarkably
`
`effective. Indeed, after Genentech revealed the results of its clinical studies, the scientific
`
`community hailed Herceptin® as “the beginning of a whole new wave of biological drugs that
`
`modulate the causes of cancer”1 and a sign that “the whole field of cancer research has turned a
`
`corner.”2
`
`5.
`
`Since FDA approval of Herceptin® in 1998, Genentech has worked diligently to
`
`develop new methods of using Herceptin®—including improved dosing schedules and broader
`
`indications—to expand access to therapy and improve the quality of life for millions of patients
`
`worldwide. This research has greatly expanded the number of patients who are able to benefit
`
`from Herceptin®. To further expand access to this lifesaving drug, Genentech also provides
`
`Herceptin® free of charge to patients who are uninsured or cannot afford treatment and assists
`
`1 Gina Kolata and Lawrence M. Fisher, Drugs to Fight Breast Cancer Near Approval, NEW YORK
`TIMES (FRONT PAGE) (Sept. 3, 1998).
`
`2 Robert Langreth, Breast-Cancer Drug Is Backed by FDA Panel, Wall Street J. (Sept. 3, 1998).
`
`ME1 29001636v.1
`
` 2 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 4 of 57 PageID #: 26336
`
`with out-of-pocket prescription-related expenses. All told, Genentech has spent over two
`
`decades, and billions of dollars, developing Herceptin® into the life-saving drug it is today.
`
`6.
`
`Genentech’s groundbreaking work developing Herceptin® was the result of years
`
`of research from a group of talented scientists. The United States Patent and Trademark Office
`
`recognized that innovative work by granting Genentech numerous patents claiming Herceptin®, its
`
`manufacture, and its use. And as one of the pioneers in the biotechnology field, Genentech
`
`collaborated with scientists at research institutions such as the City of Hope to make foundational
`
`inventions, such as efficient techniques for making antibodies that can be used as drugs.
`
`7.
`
`Seeking to profit from the success of Plaintiffs’Genentech’s innovations, Amgen is
`
`seekingsought FDA approval of a biosimilar version of Herceptin® called ABP 980. ABP 980 is a
`
`copycat product for (trastuzumab-anns). The FDA approved ABP 980, which Amgen is
`
`seekingmarkets under the tradename Kanjinti, on June 13, 2019 for the same label indications and
`
`usage as Herceptin®. In fact, Amgen is relyingrelied upon Genentech’s own studies
`
`demonstrating the safety and efficacy of Herceptin® to obtain approval of its biosimilar product.
`
`8.
`
`In 2010, Congress provided a pathway for resolving patent disputes relating to
`
`biosimilar products through the Biologics Price Competition and Innovation Act (“BPCIA”).
`
`Amgen initially purported to follow the process outlined in the BPCIA, which requires biosimilar
`
`applicants and innovator companies to exchange certain information concerning the biosimilar
`
`product and the patents that may be infringed by the manufacture and sale of the biosimilar
`
`product. See 42 U.S.C. § 262(l).
`
`9.
`
`PlaintiffsGenentech thus bringbrings this action for infringement pursuant to 35
`
`U.S.C. § 271(e)(2) based upon Amgen’s submission of its aBLA Abbreviated Biologics License
`
`Application (“aBLA”) for ABP 980. Plaintiffs also seek Genentech also seeks a judgment of
`
`ME1 29001636v.1
`
` 3 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 5 of 57 PageID #: 26337
`
`infringement under 35 U.S.C. § 271(a), (b), and (g) that Amgen’s manufacture, use, offer to sell,
`
`sale, or importation into the United States of Amgen’s biosimilar product has infringed the patents
`
`described below. Genentech also seeks a declaratory judgment pursuant to 42 U.S.C. § 262(l)(9)
`
`and 28 U.S.C. § 2201 that the manufacture, use, offer to sell, sale, or importation into the United
`
`States of Amgen’s biosimilar product would infringe the patents described below. Pursuant to 35
`
`U.S.C. § 271(e)(4)(B), 42 U.S.C. § 262(l)(8)(B), 35 U.S.C. § 271(a), (b), (g), and/or 35 U.S.C.
`
`§ 283, PlaintiffsGenentech also seekseeks a preliminary and/or permanent injunction barring
`
`Amgen’s manufacture, use, offer to sell, sale, or importation of its biosimilar product prior to the
`
`expiration of those patents. In the event that Amgen imports, manufactures, or launches its
`
`biosimilar product, and/or otherwise practices the patented inventions in the United States prior to
`
`the expiration of those patents, Plaintiffs also seekGenentech also seeks monetary damages,
`
`including lost profits and/or a reasonable royalty, for Amgen’s infringement of Genentech’s
`
`patents, and any further relief as this Court may deem just and proper.
`
`PARTIES
`
`10.
`
`Plaintiff Genentech is a corporation organized and existing under the laws of the
`
`State of Delaware with its corporate headquarters at 1 DNA Way, South San Francisco,
`
`California 94080.
`
`11.
`
`Genentech was founded in 1976 and for four decades has been at the forefront of
`
`innovation in the field of therapeutic biotechnology. Today, Genentech employs a large number
`
`of researchers, scientists, and post-doctoral staff members who routinely publish in top peer-
`
`reviewed journals and are among the leaders in total citations to their work by researchers.
`
`Genentech currently markets numerous approved pharmaceutical and biologic drugs for a range
`
`ME1 29001636v.1
`
` 4 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 6 of 57 PageID #: 26338
`
`of serious or life-threatening medical conditions, including various forms of cancer, heart attacks,
`
`strokes, rheumatoid arthritis, and respiratory diseases.
`
`12. Plaintiff City of Hope is a California not-for-profit organization, with its principal
`
`place of business at 1500 East Duarte Road, Duarte, California 91010.
`
`13. Founded in 1913, the City of Hope is a leading research hospital that incorporates
`
`cutting-edge research into patient care for cancer, diabetes, and other serious diseases.
`
`12.
`
`14. Upon information and belief, Defendant Amgen is a company organized and
`
`existing under the laws of the State of Delaware with its principal place of business located at One
`
`Amgen Center Drive, Thousand Oaks, California 91320.
`
`13.
`
`15. Amgen is, among other things, engaged in the development of biologic drugs,
`
`including a proposed biosimilar version of Genentech’s Herceptin® product, ABP 980 (“Amgen’s
`
`aBLA product”). Upon information and belief, Amgen’s aBLA product is or will be distributed
`
`and sold in the State of Delaware and throughout the United States.
`
`JURISDICTION AND VENUE
`
`14.
`
`16. This action arises under the BPCIA, 42 U.S.C. § 262(l) and the Patent Laws of
`
`the United States, Title 35, United States Code, and the Declaratory Judgment Act, 28 U.S.C.
`
`§§ 2201-2202. This Court has subject matter jurisdiction pursuant to 28 U.S.C. §§ 1331, 1332,
`
`and 1338.
`
`15.
`
`17. Venue is proper with respect to Amgen in this Court pursuant to 28 U.S.C.
`
`§§ 1391 and 1400(b) because Amgen is incorporated in Delaware.
`
`16.
`
`18. This Court has personal jurisdiction over Amgen because it is incorporated in
`
`Delaware. In addition, among other things, Amgen has filed an Abbreviated Biologics License
`
`Application (“aBLA”) for ABP 980 withbeen approved by the FDA seeking approval to market it,
`
`ME1 29001636v.1
`
` 5 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 7 of 57 PageID #: 26339
`
`which reliably indicates that it will market its proposed biosimilarits aBLA product and has
`
`announced that its aBLA product is now available to customers in the United States, including in
`
`Delaware if approved.
`
`THE PARTIES’ EXCHANGES UNDER THE BPCIA
`
`17.
`
`19. On July 31, 2017, Amgen announced that it had submitted an aBLA for ABP
`
`980 to the FDA seeking approval for the commercial manufacture, use, offer for sale, or sale of
`
`the Amgen aBLA product, a biosimilar version of trastuzumab, which is subject to BLA No.
`
`103792 to Genentech.3
`
`18.
`
`19.
`
`20. The FDA accepted Amgen’s aBLA for review on September 26, 2017.
`
`21. On October 16, 2017, Amgen provided Genentech with a copy of Amgen’s
`
`aBLA, which included a small amount of manufacturing information.
`
`20.
`
`22. On November 3, 2017, Amgen provided Genentech with additional
`
`manufacturing information regarding Amgen’s aBLA product.
`
`21.
`
`23. Genentech responded on November 20, 2017, to identify deficiencies in
`
`Amgen’s production of manufacturing information and request specific information concerning
`
`the manufacture of Amgen’s biosimilar product. Amgen provided additional manufacturing
`
`information on December 1, 2017, and December 4, 2017, but did not satisfy its disclosure
`
`obligations. Genentech then responded on December 15, 2017, to explain that Amgen’s
`
`production was deficient in that it failed to provide all of the requested information in
`
`contravention of 42 U.S.C. § 262(l)(2).
`
`3 http://www.amgen.com/media/news-releases/2017/07/amgen-and-allergan-submit-biosimilar-
`biologics-license-application-for-abp-980-to-us-food-and-drug-administration/
`
`ME1 29001636v.1
`
` 6 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 8 of 57 PageID #: 26340
`
`22.
`
`24. Amgen did not disclose all of the information relevant to establishing whether
`
`the manufacture of Amgen’s aBLA product will infringe each of the patents identified on
`
`Genentech’s operative list pursuant to 42 U.S.C. § 262(l)(3)(A), despite Genentech’s request that
`
`Amgen provide sufficient “other information that describes the process or processes used to
`
`manufacture” as required by 42 U.S.C. § 262(l)(A). Amgen’s failure to provide sufficient
`
`information under those circumstances justifies Genentech’s contention that manufacturing
`
`Amgen’s aBLA product will infringe such patents.
`
`23.
`
`25. Despite Amgen’s non-compliance (and without waiving Genentech’s objection
`
`to such non-compliance), Genentech provided its operative list of 36 patents pursuant to 42
`
`U.S.C. § 262(l)(3)(A) on December 15, 2017.
`
`24.
`
`26. Amgen replied on December 20, 2017, to assert its position that it had
`
`complied with its disclosure obligations based on Amgen’s earlier production of its aBLA and two
`
`manufacturing documents.
`
`25.
`
`27. Genentech responded on December 27, 2017, to reiterate that Amgen’s
`
`production was insufficient to provide Genentech with a complete understanding of Amgen’s
`
`trastuzumab manufacturing process.
`
`26.
`
`28. Amgen replied on February 1, 2018, with an additional supplemental
`
`production.
`
`27.
`
`29. On February 6, 2018, Genentech supplemented its § 262(l)(3)(A) list to
`
`include a newly issued manufacturing patent: U.S. Patent No. 9,868,760.
`
`28.
`
`30. On February 13, 2018, Amgen purported to provide its detailed statement
`
`concerning non-infringement and invalidity pursuant to 42 U.S.C. § 262(l)(3)(B) (“Amgen’s 3B
`
`Statement”). Amgen’s 3B Statement was deficient in numerous ways. For example, it—like
`
`ME1 29001636v.1
`
` 7 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 9 of 57 PageID #: 26341
`
`Amgen’s document productions—failed to fully describe Amgen’s manufacturing process, such
`
`that Genentech was unable to evaluate many of Amgen’s non-infringement arguments.
`
`29.
`
`31. On February 27, 2018, March 12, 2018, and April 13, 2018, Amgen produced
`
`additional documents regarding Amgen’s correspondence with the FDA regarding its aBLA
`
`submission. These supplemental productions still failed to fully describe Amgen’s manufacturing
`
`process.
`
`30.
`
`32. On April 13, 2018, and subject to its objections, Genentech provided its
`
`response to Amgen’s 3C Statement pursuant to 42 U.S.C. § 262(l)(3)(C) (“Genentech’s 3C
`
`Statement”). Genentech included responses to Amgen’s non-infringement and invalidity
`
`statements for each of the patents addressed in Amgen’s 3B Statement and maintained that ABP
`
`980 will infringe at least 18 Genentech patents. With its 3C Statement, Genentech proposed that
`
`Amgen agree that all 18 of these patents be included in a first-phase infringement action under
`
`§ 262(l)(6).
`
`31.
`
`33. On April 25, 2018, and April 30, 2018, Amgen produced additional documents
`
`regarding Amgen’s correspondence with the FDA regarding its aBLA submission. These
`
`supplemental productions still failed to fully describe Amgen’s manufacturing process.
`
`32.
`
`34. After Genentech served its 3C Statement, the parties initiated negotiations
`
`under § 262(l)(4). On May 23, 2018, Genentech and Amgen agreed that the 37 patents addressed
`
`in the exhibits to Genentech’s 3C Statement shall be the subject of an action for patent
`infringement under § 262(l)(6).
`parties’ agreement. This action is Genentech’s action pursuant to § 262(l)(6)(A).
`
`33.
`
`35. In light of the parties’ agreement, § 262(l)(6)(A) required Genentech to bring
`
`an action for patent infringement with respect to each of the 37 patents that were part of the
`
`ME1 29001636v.1
`
` 8 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 10 of 57 PageID #: 26342
`
`34.
`
`36. On May 15, 2018, while the parties’ negotiations pursuant to § 262(l)(4) were
`
`underway, Amgen purported to notify Genentech pursuant to 42 U.S.C. § 262(l)(8)(A) that it
`
`intends to commence commercial marketing of ABP 980 in the United States no earlier than 180
`
`from May 15, 2018 (i.e., October 28, 2018).
`
`35.
`
`37. On June 21, 2018, Genentech and City of Hope (collectively, “Plaintiffs”) sued
`
`Amgen for infringement of all 37 patents that the parties agreed to litigate during their § 262(l)(4)
`
`negotiations. On July 19, 2018, Plaintiffs and Amgen stipulated to dismiss with prejudice all
`
`claims for infringement of U.S. Patent Nos. 6,242,177, 6,489,447, 6,586,206, 6,870,034,
`
`7,449,184, 7,501,122, 8,044,017, 8,314,225, 8,357,301, 8,460,895, 8,691,232, 8,710,196,
`
`8,771,988, 9,047,438, 9,080,183, 9,428,766, 9,487,809, 9,493,744, and 9,868,760 relating to
`
`ABP 980, subject to certain conditions.
`
`36.
`
`38. In a letter dated November 7, 2018, pursuant to the Court’s scheduling order
`
`(D.I. 44), Genentech identified to Amgen a narrowed list of 10 patents which it intended to assert
`
`against Amgen in this litigation. In the same letter, Genentech notified Amgen that it intended to
`
`assert infringement of claims 10 and 11 of U.S. App. No. 14/073,659 (“the ’659 application”)
`
`once issued by the U.S. Patent Office. On December 25, 2018, the ’659 application issued as U.S.
`
`Patent No. 10,160,811 (“the ’811 patent”). Claims 6 and 7 of the ’811 patent as issued
`
`correspond to claims 10 and 11 of the ’659 application. Genentech further supplemented its
`
`supplemented its § 262(l)(3)(A) list to include the ’811 patent.
`
`37.
`
`On July 23, 2019, Plaintiffs and Amgen stipulated to dismiss with prejudice all
`
`claims for infringement of U.S. Patent Nos. 6,331,415, 7,923,221, 6,407,213, 6,417,335,
`
`9,249,218, 6,121,428, and 6,620,918 relating to ABP 980. City of Hope was dismissed as a
`
`ME1 29001636v.1
`
` 9 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 11 of 57 PageID #: 26343
`
`plaintiff to this case through that stipulation. That stipulation was so-ordered by the Court on
`
`July 24, 2019. D.I. 325
`
`38.
`
`On August 2, 2019, Genentech and Amgen stipulated to a judgment of non-
`
`infringement of U.S. Patent Nos. 8,512,983 and 9,714,293 under the Court’s claim construction
`
`of “a glutamine-free production culture medium,” while preserving Genentech’s ability to
`
`challenge that claim construction on appeal. That stipulation was so-ordered by the Court on
`
`August 20, 2019. D.I. 340.
`
`AMGEN’S aBLA PRODUCT
`
`39.
`
`Amgen has publicly stated that its aBLA product is biosimilar to Herceptin®. For
`
`example, Amgen has issued press releases claiming that ABP 980 is “a biosimilar candidate to
`
`Herceptin®” and “ABP 980 is a biosimilar candidate to trastuzumab,”4 and it has announced the
`
`results of an Amgen study that purports to conclude that “[e]fficacy, safety and immunogenicity
`
`data support ABP 980 as a trastuzumab biosimilar.”5
`
`40.
`
`Given Amgen’s claim of biosimilarity, Amgen’s aBLA product must “utilize the
`
`same mechanism or mechanisms of action [as Herceptin®] for the condition or conditions of use
`
`prescribed, recommended, or suggested in the proposed labeling.” 42 U.S.C.
`
`§ 262(k)(2)(A)(i)(II).
`
`41.
`
`Under 35 U.S.C. § 271(e)(2)(C), Amgen has committed a statutory act of patent
`
`infringement with respect to patents identified by Genentech under 42 U.S.C. § 262(l)(3), through
`
`the submission of its aBLA application for ABP 980.
`
`4 http://www.amgen.com/media/news-releases/2017/07/amgen-and-allergan-submit-biosimilar-
`biologics-license-application-for-abp-980-to-us-food-and-drug-administration/
`5 https://www.amgen.com/media/news-releases/2017/09/amgen-and-allergan-present-phase-3-
`data-on-biosimilar-trastuzumab-candidate-abp-980-at-the-european-society-for-medical-
`oncology-2017-congress/
`
`ME1 29001636v.1
`
` 10 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 12 of 57 PageID #: 26344
`
`42.
`
`43.
`
`On June 13, 2019, Amgen’s aBLA product was approved by the FDA.
`
`On July 18, 2019, Amgen issued a press release announcing that “KANJINTI™
`
`(trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab), [is] now available in the United
`
`States (U.S.).”6
`
`44.
`
`Since making its aBLA product available to customers in the United States,
`
`Amgen has stated that it “has received confirmation from its customers that they have begun
`
`administering Kanjinti® to cancer patients.”7
`
`GENENTECH’S ASSERTED PATENTS
`
`45.
`
`42. Genentech has spent over two decades and significant resources developing
`
`Herceptin®, and the USPTO has awarded to Genentech numerous patents on innovations resulting
`
`from this massive undertaking. These patents cover the antibody trastuzumab, along with its
`
`manufacture and use.
`
`46.
`
`43. Upon information and belief, Amgen’s aBLA product infringes or will infringe
`
`at least the following patents, which Genentech has asserted in this lawsuit: U.S. Patent No.
`
`6,331,415, U.S. Patent No. 7,923,221, U.S. Patent No. 6,407,213, U.S. Patent No. 7,846,441,
`
`U.S. Patent No. 7,892,549, U.S. Patent No. 6,627,196, U.S. Patent No. 7,371,379, U.S. Patent
`
`No. 10,160,811, U.S. Patent No. 6,417,335, U.S. Patent No. 9,249,218, U.S. Patent No.
`
`8,574,869, U.S. Patent No. 6,620,918, U.S. Patent No. 7,993,834, U.S. Patent No. 8,076,066,
`
`6 http://investors.amgen.com/news-releases/news-release-details/amgen-and-allergans-mvasitm-
`bevacizumab-awwb-and-kanjintitm
`7 Second Declaration of Robert Jacobson in Support of Amgen Inc.’s Opposition to Genentech,
`Inc.’s Emergency Motion for an Injunction Pending Appeal, Genentech, Inc. v. Amgen Inc., No.
`19-2156 (Fed. Cir.), ECF No. 28 (July 29, 2019).
`
`ME1 29001636v.1
`
` 11 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 13 of 57 PageID #: 26345
`
`and U.S. Patent No. 8,440,402, U.S. Patent No. 6,121,428, U.S. Patent No. 8,512,983, and U.S.
`
`Patent No. 9,714,293.
`
`The Cabilly Patents
`
`44. U.S. Patent Nos. 6,331,415 and 7,923,221 (collectively, the “Cabilly Patents”)
`
`describe and claim a process for producing monoclonal antibodies, such as Herceptin®, from
`
`recombinant DNA. This effective and efficient process applies a novel co-expression technique to
`
`produce antibody heavy and light chains in a single host cell, and has given rise to an entire
`
`industry of therapeutic monoclonal antibodies.
`
`45. U.S. Patent No. 6,331,415 (“the ’415 patent”), titled “Methods of Producing
`
`Immunoglobulins, Vectors and Transformed Host Cells for Use Therein,” was duly and legally
`
`issued by the Patent Office on December 18, 2001. A true and correct copy of the ’415 patent is
`
`attached as Exhibit A. Genentech and the City of Hope are the owners by assignment of the ’415
`
`patent.
`
`46. U.S. Patent No. 7,923,221 (“the ’221 patent”), titled “Methods of Making Antibody
`
`Heavy and Light Chains Having Specificity for a Desired Antigen,” was duly and legally issued by
`
`the Patent Office on April 12, 2011. A true and correct copy of the ’221 patent is attached as
`
`Exhibit B. Genentech and the City of Hope are the owners by assignment of the ’221 patent.
`
`The ’213 Patent
`
`47. U.S. Patent No. 6,407,213 (“the ’213 patent”) claims the Herceptin® antibody itself,
`
`along with other humanized monoclonal antibodies. The inventors of the ’213 patent discovered
`
`that by grafting the key parts of a mouse antibody onto a human antibody consensus sequence,
`
`they could create antibodies that were both tolerated by the immune system and effective to treat
`
`ME1 29001636v.1
`
` 12 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 14 of 57 PageID #: 26346
`
`diseases like HER2-positive breast cancer. The techniques described in the ’213 patent allowed
`
`scientists to efficiently design antibodies for specific disease targets by modifying mouse
`
`antibodies produced in the laboratory in specific ways so that they are compatible with a human
`
`immune system.
`
`48. The ’213 patent, titled “Method for Making Humanized Antibodies,” was duly and
`
`legally issued by the Patent Office on June 18, 2002. A true and correct copy of the ’213 patent
`
`is attached as Exhibit C. Genentech is the owner by assignment of the ’213 patent.
`
`The Combination Chemotherapy Patents
`
`47.
`
`49. U.S. Patent No. 7,846,441 (“the ’441 patent”), claims the administration of
`
`Herceptin® in combination with a chemotherapy agent known as a taxoid, in the absence of an
`
`anthracycline derivative (another chemotherapy agent) in an amount effective to extend time to
`
`disease progression without overall increase in severe adverse events. This specific method of
`
`treatment unexpectedly resulted in a significant improvement in patient outcomes. It nearly
`
`doubled the time until disease progression compared to treatment using a taxoid alone, and it also
`
`avoided the serious cardiotoxicity associated with Herceptin® in combination with anthracycline
`
`derivatives that unexpectedly presented during the Herceptin® clinical trials.
`
`48.
`
`50. The ’441 patent, titled “Treatment with Anti-ErbB2 Antibodies,” was duly and
`
`legally issued by the Patent Office on December 7, 2010. A true and correct copy of the ’441
`
`patent is attached as Exhibit DA. Genentech is the owner by assignment of the ’441 patent.
`
`49.
`
`51. U.S. Patent No. 7,892,549 (“the ’549 patent”) is a continuation to the ’441
`
`patent that claims a method of treating a patient with HER2-positive breast cancer by
`
`administering Herceptin® in combination with a taxoid and a further growth inhibitory agent or
`
`further therapeutic agent.
`
`ME1 29001636v.1
`
` 13 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 15 of 57 PageID #: 26347
`
`50.
`
`52. The ’549 patent, titled “Treatment with Anti-ErbB2 Antibodies,” was duly and
`
`legally issued by the Patent Office on February 22, 2011. A true and correct copy of the ’549
`
`patent is attached as Exhibit EB. Genentech is the owner by assignment of the ’549 patent.
`
`The Method of Administration Patents
`
`51.
`
`53. U.S. Patent Nos. 6,627,196, 7,371,379, and 10,160,811 (collectively, the
`
`“Method of Administration Patents”) generally cover the most common administration method for
`
`Herceptin®: an initial dose of 8 mg/kg, followed by 6 mg/kg doses once every three weeks.
`
`Herceptin® was initially approved for administration on a weekly regimen, but Genentech
`
`discovered that the drug could be dosed only once every three weeks without reducing safety or
`
`effectiveness. The discovery of three-weekly dosing has had a marked impact on patients’ quality
`
`of life by providing the same life-saving effects of Herceptin® while allowing patients to receive
`
`treatment less frequently.
`
`52.
`
`54. U.S. Patent No. 6,627,196 (“’196 patent”), titled “Dosages for Treatment with
`
`Anti-ErbB2 Antibodies,” was duly and legally issued by the Patent Office on September 30, 2003.
`
`A true and correct copy of the ’196 patent is attached as Exhibit GC. Genentech is the owner by
`
`assignment of the ’196 patent.
`
`53.
`
`55. U.S. Patent No. 7,371,379 (“the ’379 patent”), titled “Dosages for Treatment
`
`with Anti-ErbB2 Antibodies,” was duly and legally issued by the Patent Office on May 13, 2008.
`
`A true and correct copy of the ’379 patent is attached as Exhibit HD. Genentech is the owner by
`
`assignment of the ’379 patent.
`
`54.
`
`56. U.S. Patent No. 10,160,811 (“the ’811 patent”), titled “Treatment with Anti-
`
`ErbB2 Antibodies,” was duly and legally issued by the Patent Office on December 25, 2018. A
`
`ME1 29001636v.1
`
` 14 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 16 of 57 PageID #: 26348
`
`true and correct copy of the ’811 patent is attached as Exhibit FE. Genentech is the owner by
`
`assignment of the ’811 patent.
`
`The Acidic Variants Patents
`
`57. U.S. Patent Nos. 6,417,335 and 9,249,218 (collectively, the “Acidic Variants
`
`Patents”) cover compositions with reduced amounts of more acidic structural variants of
`
`trastuzumab (“acidic variants”) and chromatographic processes for removing these acidic variants
`
`during purification. Some trastuzumab acidic variants have lower potency than trastuzumab itself.
`
`The Acidic Variants Patents describe and claim chromatographic processes and compositions that
`
`ensure the Herceptin® drug product is uniformly pure and effective.
`
`58. U.S. Patent No. 6,417,335 (“the ’335 patent”), titled “Protein Purification,” was duly
`
`and legally issued by the Patent Office on July 9, 2002. A true and correct copy of the ’335
`
`patent is attached as Exhibit I. Genentech is the owner by assignment of the ’335 patent.
`
`59. U.S. Patent No. 9,249,218 (“the ’218 patent”), titled “Protein Purification,” was duly
`
`and legally issued by the Patent Office on February 2, 2016. A true and correct copy of the ’218
`
`patent is attached as Exhibit J. Genentech is the owner by assignment of the ’218 patent.
`
`HER2 Diagnostic Patents
`
`55.
`
`60. U.S. Patent Nos. 7,993,834, 8,076,066, and 8,440,402 claim novel techniques
`
`for identifying patients who might benefit from trastuzumab therapy using gene amplification
`
`techniques even where immunohistochemistry techniques suggest that the patient may not
`
`overexpress HER2.
`
`56.
`
`61. U.S. Patent No. 7,993,834 (“the ’834 patent”), titled “Detection of ErbB2
`
`Gene Amplification to Increase the Likelihood of the Effectiveness of ErbB2 Antibody Breast
`
`ME1 29001636v.1
`
` 15 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 17 of 57 PageID #: 26349
`
`Cancer Therapy,” was duly and legally issued by the Patent Office on August 9, 2011. A true and
`
`correct copy of the ’834 patent is attached as Exhibit KF. Genentech is the owner by assignment
`
`of the ’834 patent.
`
`57.
`
`62. U.S. Patent No. 8,076,066 (“the ’066 patent”), titled “Gene Detection Assay
`
`for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy,”
`
`was duly and legally issued by the Patent Office on December 13, 2011. A true and correct copy
`
`of the ’066 patent is attached as Exhibit LG. Genentech is the owner by assignment of the ’066
`
`patent.
`
`58.
`
`63. U.S. Patent No. 8,440,402 (“the ’402 patent”), titled “Gene Detection Assay
`
`for Improving the Likelihood of an Effective Response to a HER2 Antibody Cancer Therapy,”
`
`was duly and legally issued by the Patent Office on May 14, 2013. A true and correct copy of the
`
`’402 patent is attached as Exhibit MH. Genentech is the owner by assignment of the ’402 patent.
`
`The Kao Patent
`Cell Culture, Purification, and Antibody Manufacturing Patents
`
`64. U.S. Patent Nos. 6,121,428, 6,620,918, 8,512,983, 8,574,869, and 9,714,293 claim
`
`novel techniques developed by Genentech relating to various aspects of cell culture, purification,
`
`and antibody purification.
`
`65. U.S. Patent No. 6,121,428 (“the ’428 patent”), titled “Protein Recovery,” was duly
`
`and legally issued by the Patent Office on September 19, 2000. A true and correct copy of the
`
`’428 patent is attached as Exhibit N. Genentech is the owner by assignment of the ’428 patent.
`
`66. U.S. Patent No. 6,620,918 (“the ’918 patent”), titled “Separation of Polypeptide
`
`Monomers,” was duly and legally issued by the Patent Office on September 16, 2003. A true and
`
`ME1 29001636v.1
`
` 16 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 18 of 57 PageID #: 26350
`
`correct copy of the ’918 patent is attached as Exhibit O. Genentech is the owner by assignment
`
`of the ’918 patent.
`
`67. U.S. Patent No. 8,512,983 (“the ’983 patent”), titled “Production of Proteins in
`
`Glutamine-Free Cell Culture Media,” was duly and legally issued by the Patent Office on August
`
`20, 2013. A true and correct copy of the ’983 patent is attached as Exhibit P. Genentech is the
`
`owner by assignment of the ’983 patent.
`
`59.
`
`68. U.S. Patent No. 8,574,869 (“the ’869 patent”), titled “Prevention of Disulfide
`
`Bond Reduction During Recombinant Production of Polypeptides,” was duly and legally issued by
`
`the Patent Office on November 5, 2013. A true and correct copy of the ’869 patent is attached as
`
`Exhibit QI. Genentech is the owner by assignment of the ’869 patent.
`
`69. U.S. Patent No. 9,714,293 (“the ’293 patent”), titled “Production of Proteins in
`
`Glutamine-Free Cell Culture Media,” was duly and legally issued by the Patent Office on July 25,
`
`2017. A true and correct copy of the ’293 patent is attached as Exhibit R. Genentech is the
`
`owner by assignment of the ’293 patent.
`
`COUNT I
`INFRINGEMENT OF U.S. PATENT NO. 6,331,4157,846,441
`
`60.
`
`70. Plaintiffs incorporateGenentech incorporates by reference paragraphs 1-6959
`
`as if fully set forth herein.
`
`71. Upon review of publicly available information and/or information provided by Amgen
`
`pursuant to 42 U.S.C. § 262(l)(2), Plaintiffs believe that a claim of patent infringement, either
`
`literally or under the doctrine of equivalents, could reasonably be asserted by Plaintiffs if a person
`
`not licensed by Plaintiffs engaged in the making, using, offering to sell, selling, or importing into
`
`the United States of ABP 980 prior to the expiration of the ’415 patent. Genentech included the
`
`ME1 29001636v.1
`
` 17 - -
`
`-
`

`

`Case 1:18-cv-00924-CFC Document 344-2 Filed 08/27/19 Page 19 of 57 PageID #: 26351
`
`’415 patent in its disclosure of patents pursuant to 42 U.S.C. § 262(l)(3)(A). Genentech also
`
`provid